Journal Mobile Options
Table of Contents
Vol. 41, No. 6, 2008
Issue release date: October 2008
Psychopathology 2008;41:371–378

Cannabis-Induced Psychotic-Like Experiences Are Predicted by High Schizotypy

Confirmation of Preliminary Results in a Large Cohort

Stirling J. · Barkus E.J. · Nabosi L. · Irshad S. · Roemer G. · Schreudergoidheijt B. · Lewis S.
aDepartment of Psychology and Speech Pathology, Manchester Metropolitan University, Manchester, and bInstitute of Psychiatry, Kings College, London, cNeuroscience and Psychiatry Unit, University of Manchester, Manchester, UK; dDepartment for Psychodiagnostics, Saxion HSIJ, Deventer, The Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Cannabis use has been identified as a possible risk factor for developing schizophrenia. In a previous paper we reported preliminary evidence that cannabis use increases the likelihood of psychosis-like experiences in non-clinical respondents who scored highly on a measure of schizotypy. We now present findings from pooled data from 3 new follow-up studies comprising a sample of 477 respondents, of whom 332 reported using cannabis at least once. Sampling and Methods: As in our previous study, the psychological effects of cannabis were assessed with the Cannabis Experiences Questionnaire, from which 3 subscales can be derived; encompassing pleasurable experiences, psychosis-like experiences and after-effects. The respondents also completed the brief Schizotypal Personality Questionnaire. Results: Cannabis use was reported by 70% of the sample. Use per se was not significantly related to schizotypy. However, high scoring schizotypes were more likely to report both psychosis-like experiences and unpleasant after-effects associated with cannabis use. The pleasurable effects of cannabis use were not related to schizotypy. Exploratory factor analysis of the pooled data from this study and our previous report (providing a sample of >400 cannabis users) suggested a 3-factor solution. These were characterised as a psychotic-dysphoric index (factor 1), an expansive index (factor 2) and an intoxicated index (factor 3). Schizotypy was highly correlated with factors 1 and 3, though not with factor 2. Conclusion: High scoring schizotypes who use cannabis are more likely to experience psychotic-dysphoric phenomena and intoxicating effects during and after use. Our results confirm and expand the findings reported in our previous study. They are consistent with the hypothesis that cannabis use may be a risk factor for full psychosis in this group.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Linszen DH, Dingemans PM, Lenoir ME: Cannabis abuse and the course of recent onset schizophrenia disorders. Arch Gen Psychiatry 1994;51:273–279.
  2. Baigent M, Holme G, Hafner RJ: Self-reports of the interaction between substance abuse and schizophrenia. Aust NZ J Psychiatry 1995;29:69–74.
  3. Van Os J, Bak M, Hanssen M, Bijl JL, De Graaf R, Verdoux H: Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002;156:319–327.
  4. Degenhardt L, Hall W: The association between psychosis and problematic drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychol Med 2001;31:659–668.
  5. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray R: Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995;15:277–281.
  6. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffit TE: Cannabis use in adolescence and risk for adult psychosis: a longitudinal prospective study. BMJ 2002;325:1212–1213.
  7. Schiffman J, Nakamura B, Earleywine M, LaBrie J: Symptoms of schizotypy precede cannabis use. Psychiatry Res 2005;134:37–42.
  8. Fergusson DM, Horwood LJ, Swain-Campbell NR: Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003;33:15–21.
  9. Williams JH, Wellman JN, Rawlins J: Cannabis use correlates with schizotypy in healthy people. Addiction 1996;91:869–877.
  10. Kwapil TR: A longitudinal study of drug and alcohol use by psychosis-prone and impulsive non-conforming individuals. J Abnorm Psychol 1996;105:114–123.
  11. Mass R, Bardong C, Kindl K, Dahme B: Relationship between cannabis use, schizotypal traits and cognitive function in healthy subjects. Psychopathology 2001;34:209–214.
  12. Dumas P, Saoud M, Bouafia S, Gutknecht C, Ecohard R, Dalery J, Rochet T, D’Amato T: Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Res 2002;109:27–35.
  13. Skosnik PD, Spatz-Glenn L, Park S: Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res 2001;48:83–92.
  14. Thomas H: A community survey of adverse effects of cannabis use. Drug Alcohol Depend 1996;42:201–207.
  15. Verdoux H, Sorbara F, Gindre C, Swendsen JD, van Os J: Cannabis use and dimensions of psychosis in a non-clinical population of female subjects. Schizophr Res 2002;59:77–84.
  16. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD: Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med 2003;33:23–32.
  17. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J: Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2004;330:11–14.
  18. Caspi A, Moffitt E, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW: Moderation of the effect of adolescent onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biol Psychiatry 2005;57:1117–1127.
  19. Barkus EJ, Stirling J, Hopkins RS, Lewis S: Cannabis-induced psychotic-like experiences are associated with high schizotypy. Psychopathology 2006;39:175–178.
  20. Raine A, Benishay D: The SPQ-B: a brief screening instrument for schizotypal personality disorder. Schizophr Bull 1995;23:75–82.

    External Resources

  21. Raine A: The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991;17:555–564.
  22. Abood ME, Martin BR: Neurobiology of marijuana abuse. Trends Pharmacol Sci 1991;13:201–206.
  23. Ames R: A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model of psychoses. J Ment Sci 1958;104:972–999.
  24. Keeler M, Ewing J, Rouse B: Hallucinogenic effects of marijuana as currently used. Am J Psychiatry 1971;128:213–216.
  25. Hammer T, Vaglum P: Initiation, continuation or discontinuation of cannabis use in the general population. Br J Addict 1990;85:899–909.
  26. Peters E, Joseph S, Day S, Garety P: Measuring delusional ideation: the 21-item Peters et al delusions inventory (PDI). Schizophr Bull 2004;30:555–564.
  27. Stirling J, Barkus E, Lewis S: Hallucination proneness, schizotypy and meta-cognition. Behav Res Ther 2007;45:1401–1408.
  28. Verdoux H, Van Os J: Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res 2002;54:59–65.
  29. Daderman A-M, Meurling A, Hallman J: Different personality patterns of non-socializing (juvenile delinquents) and socialized (air force pilot recruits) sensation seekers. Eur J Pers 2001;15:239–252.
  30. Gaoni Y, Mechoulon R: Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646–1647.
  31. Herkenham M, Lynn AB, Little MD, Ross-Johnson M, Melvin LS, De Costa BR, Rice KC: Cannabinoid receptor localization in the brain. Proc Natl Acad Sci USA 1990;87:1932–1936.
  32. Tanda G, Pontieri FE, DiChiara G: Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;276:2048–2050.
  33. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG: Cannabis-induced dopamine release: an in vivo SPECT study. Psychiatry Res 2001;107:173–177.
  34. Laruelle M: The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Rev 2000;31:371–384.
  35. Van Os J, Hanssen M, Bijl RV, Ravelli A: Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res 2000;45:11–20.
  36. D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y, Braley G, Gueorguieva R, Krystal JH: The psychotomimetic effects of intravenous delta 9 tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29:1558–1572.
  37. Koethe D, Gerth CW, Neatby MA, Haensel A, Thies M, Schneider U, Emrich HM, Klosterkotter J, Schultze-Lutter F, Leweke F: Disturbances of visual information processing in early states of psychosis and experimental delta 9 THC altered states of consciousness. Schizophr Res 2006;88:142–150.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50